High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study

Lancet

Volumn 358, Issue 9298, 2001, Pages 2026-2033

  Walldius, Göran ^a,b   Jungner, Ingmar ^c   Holme, Ingar ^d   Aastveit, Are H ^e   Kolar, Werner ^c   Steiner, Eugen ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ST GÖRAN S HOSPITAL   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035894648     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)07098-2     Document Type: Article

References (35)

1. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
2. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham offspring study
3. Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group
4. Apolipoprotein B and coronary artery disease in women: A cross-sectional study in women undergoing their first coronary angiography
5. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease
6. Relationship between HDL-cholesterol and apolipoprotein A-I and the severity of coronary artery disease
7. Coronary artery disease in patients at low risk: Apolipoprotein AI as an independent risk factor
8. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease
9. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material
10. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material
11. Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein (a) in a population sample
12. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham offspring study
13. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham offspring study
14. Apolipoprotein B and A-I distributions in the United States, 1988-1991: Results of the National Health and Nutrition Examination Survey III (NHANES III)
15. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Québec and Saskatchewan
16. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization: International Federation of Clinical Chemistry first international reference materials
17. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study
18. Thrombogenic factors and recurrent coronary events
19. LDL size and risk of coronary heart disease in elderly men and women
20. High cholesterol and triglyceride values in Swedish males and females: Increased risk of fatal myocardial infarction: First report from the AMORIS (Apolipoprotein-related MOrtality RISk) study
21. Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females
22. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
23. Measurement of apolipoproteins: Time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias
24. Counterpoint: To (measure apo) B or not to (measure apo) B: A critique of modern medical decision-making
25. Apolipoprotein B versus lipoprotein lipids: Vital lessons from the AFCAPS/TexCAPS trial
26. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
27. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Québec cardiovascular study
28. Atherogenicity of triglyceride-rich lipoproteins
29. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
30. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
31. Relation between baseline and on-treatment lipid parameters and first fatal major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
32. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events
33. Treatment of dyslipidemia: Room for improvement?
34. Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory